Hikma launches levocarnitine injection
Levocarnitine injection is indicated for the acute and chronic treatment of patients with an inborn error of metabolism.
Hikma has launched levocarnitine injection in a 1g/5ml dose.
The product is indicated for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. It also is indicated for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease who are undergoing dialysis.
[Read more: Hikma intros Kloxxado]
Levocarnitine injection, 1g/5ml had a market value of approximately $27 million in the 12 months ending July 2023, per IQVIA.